Bayer flags strong results of prostate cancer drug

June 6, 2011

German chemical and pharmaceutical group Bayer said Monday that its Alpharadin treatment for prostate cancer has shown positive results in advanced trials.

Bayer developed Alpharadin with the Norwegian lab Algeta and tested it on 922 people in Phase III trials, a statement said.

Those on the treatment lived an average 14 months after the course began, compared with an average of 11.2 months for those given a placebo, it added.

The tests were abandoned early to allow the latter to be given Alpharadin as well.

It has not yet been approved for general sale but Bayer has placed strong hopes in the compound, radium-223 chloride, which attacks in bones.

"Around 90 percent of men with advanced prostate cancer have which are the main cause of disability and death in this disease," the statement said.

Prostate cancer is the most frequent form of cancer among men in Northern Europe and the United States. In 2008, an estimated 903,000 men had worldwide and 250,000 died from the disease, Bayer said.

The news was welcomed on Frankfurt's stock exchange, where Bayer shares gained 1.98 percent to 56.53 euros to lead gainers on the DAX index which was 0.27 percent lower overall.

Related Stories

Recommended for you

High rate of antidepressant use after cancer

October 26, 2016

(HealthDay)—Treatment for depression and anxiety is nearly twice as common among U.S. cancer survivors as it is for those who never had the disease, a new study finds.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.